Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31708134 | 0.86 | SLC22A6 (0.47) | SLC22A6ALOX5NR4A2MTNR1AMTNR1B | |
| SCHEMBL30276861 | 0.83 | ALOX5 (0.44) | SLC22A6ALOX5NR4A2MTNR1AMTNR1B | |
| SCHEMBL30712078 | 0.82 | SLC22A6 (0.50) | SLC22A6NR4A2MTNR1AMTNR1B | |
| SCHEMBL31708098 | 0.81 | ALOX5 (0.43) | SLC22A6ALOX5NR4A2MTNR1AMTNR1B | |
| SCHEMBL31708071 | 0.81 | RAB9A (0.52) | SLC22A6NR4A2MTNR1AMTNR1B | |
| SCHEMBL29504147 | 0.81 | SLC22A6 (0.49) | SLC22A6NR4A2MTNR1AMTNR1B | |
| SCHEMBL20898149 | 0.81 | SLC22A6 (0.49) | SLC22A6NR4A2MTNR1AMTNR1B | |
| SCHEMBL31027232 | 0.81 | HTR2A (0.48) | ALOX5 | |
| SCHEMBL24499527 | 0.81 | SLC22A6 (0.44) | SLC22A6NR4A2MTNR1AMTNR1B | |
| SCHEMBL31380080 | 0.81 | SLC22A6 (0.44) | SLC22A6NR4A2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635492-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |